Holen Sie sich die Stockscreener-App
32.85
2.46%
-0.83
Handel nachbörslich:
32.52
-0.33
-1.00%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Why hedge funds are buying Stoke Therapeutics Inc. stockGrip and Outsole Review & size guide reminders to avoid returns - ulpravda.ru
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - ulpravda.ru
Is Stoke Therapeutics Inc. stock a buy in volatile marketsQuarterly Market Review & Fast Gaining Stock Strategy Reports - ulpravda.ru
Fed Meeting: Is Stoke Therapeutics Inc. stock vulnerable to regulatory risksMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Breakouts Watch: Will Stoke Therapeutics Inc. stock gain from strong economyQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - ulpravda.ru
EBIT per share of Stoke Therapeutics, Inc. – MUN:0GT - TradingView — Track All Markets
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Tangible book value per share of Stoke Therapeutics, Inc. – DUS:0GT - TradingView — Track All Markets
Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock By Investing.com - Investing.com UK
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat
Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus
Chardan Capital Markets assumes coverage on Stoke Therapeutics stock with Buy rating - Investing.com Canada
Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation - MSN
Stoke Therapeutics (STU:0GT) EV-to-OCF : 25.98 (As of Dec. 23, 2025) - GuruFocus
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus
Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS
Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright - Investing.com Nigeria
HC Wainwright & Co. Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Stoke Therapeutics Inc diskutieren - sharewise.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat
STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Dir Kaye Sells 13,430 ($433.4K) Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
STOK Crosses Above Average Analyst Target - Nasdaq
Officer Allan Files To Sell 3,978 Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics highlights Zorevunersen’s potential at epilepsy meeting - MSN
Biogen, Stoke Therapeutics announce data presentations for zorevunersen - MSN
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):